Specialty pharmacy cost management strategies of private health care payers

Journal of Managed Care Pharmacy

Volumn 12, Issue 9, 2006, Pages 736-744

  Stern, Debbie ^a   Reissman, Debi ^a  

^a Rxperts Inc   (United States)

Author keywords

Benefit design; Biotechnology; Injectable drugs; Reimbursement; Specialty pharmacy

Indexed keywords

ABATACEPT; ADALIMUMAB; BETA1A INTERFERON; CONSENSUS INTERFERON; CYCLOSPORIN; DACLIZUMAB; ERLOTINIB; ETANERCEPT; FLUOROURACIL; GEFITINIB; GLATIRAMER; HUMAN GROWTH HORMONE; IMATINIB; INFLIXIMAB; INTERFERON BETA SERINE; LENALIDOMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PARATHYROID HORMONE[1-34]; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; REBETRON; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT FOLLITROPIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SORAFENIB; SUNITINIB; TEV TROPIN; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; DRUG;

BILLING AND CLAIMS; CANCER; CODING AND CLASSIFICATION; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG CLASSIFICATION; DRUG COST; DRUG FORMULARY; DRUG INDUSTRY; GRAFT REJECTION; GROWTH HORMONE DEFICIENCY; HEALTH CARE ACCESS; HEALTH CARE PLANNING; HEMOPHILIA; HEPATITIS C; HUMAN; INFERTILITY; MEDICARE; MULTIPLE SCLEROSIS; OSTEOPOROSIS; PHARMACEUTICAL CARE; PHARMACIST; PHARMACY; PRIVATE PRACTICE; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TREATMENT OUTCOME; ARTICLE; COST; COST CONTROL; DRUG UTILIZATION; ECONOMICS; HEALTH INSURANCE; INJECTION; ORGANIZATION AND MANAGEMENT; UNITED STATES;

COST CONTROL; COST SHARING; COSTS AND COST ANALYSIS; DRUG COSTS; DRUG UTILIZATION; HUMANS; INJECTIONS; INSURANCE, HEALTH; PHARMACEUTICAL PREPARATIONS; PHARMACEUTICAL SERVICES; UNITED STATES;

EID: 33847299170     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2006.12.9.736     Document Type: Review

References (43)

1. Pharmaceutical Research and Manufacturers of America. Medicines in development: biotechnology, 2004 survey. Available at: http://www.phrma.org/ files/Biotech%20Survey.pdf. Accessed February 25, 2006.
2. Medco. Medco 2005 Drug Trend Report: Managing Generation RX: How to Balance Cost and Care. Franklin Lakes, NJ: Medco; 2005.
3. Aon. Fall 2005 Health Care Trend Survey. Chicago, IL: Aon; 2005.
4. Fontanez C, McDermott R, Whitehead D. 2004 Specialty Pharmacy Management Guide & Trend Report. St. Louis, MO: CuraScript Pharmacy; June 2005.
5. In the context of this article, "private health care payers" includes health plans, employers that purchase health care coverage through health plans, and employers that insure their own health care costs and are noted collectively in the text as "payers."
6. As consultants involved in managed care pharmacy, the authors are exposed to various payer strategies. Sources of general market intelligence include market research interviews, focus groups, and direct consulting with health plans, PBMs, employers, and specialty pharmacies.
7. Nagle PC, Lugo TF, Nicita CA. Defining and characterizing the late-stage biopharmaceutical pipeline. Am J Manag Care. 2003;9(6):S124-S135.
8. Centers for Medicare & Medicaid Services. Medicare Modernization Act: 2007 Final Guidelines - Formularies, CY07 Formulary Guidance. Washington DC: CMS; 2006.
9. Caremark. TrendsRx Report. Northbrook, IL: Caremark; 2006.
10. Serono. Serono Injectables Digest. 2nd ed. Rockland, MA: Serono; 2006.
11. Novartis. Novartis Pharmacy Benefit Report Facts and Figures. 2005 ed. New Jersey: Novartis; 2005.
12. Centers for Medicare & Medicaid Services. Medicare Part B versus Part D coverage issues. Available at: http://www.cms.hhs.gov/ PrescriptionDrugCovGenIn/Downloads/ PartBandPartDdoc_07.27.05.pdf. Accessed October 26, 2006.
13. American Medical Association. Healthcare Common Procedures Coding System. Atlanta, GA: Ingenix Publishing Group; 2005.
14. Health Insurance Portability & Accountability Act of 1996. Public Law 10-191. August 1996.
15. Centers for Medicare & Medicaid Services. Medicare Part B drug average sales price. Available at: http://www.cms.hhs.gov/ McrPartBDrugAvgSalesPrice/. Accessed October 15, 2006.
16. Rubenstein, EB. Timeline and potential impact of CMS's Competitive Acquisition Program (CAP). J Manag Care Pharm. 2006;12(3):263-64. Available at: http://www.amcp.org/data/jmcp/Commentary_264-265.pdf. Accessed November 5, 2006.
17. Academy of Managed Care Pharmacy. Where we stand on any willing provider legislation: 2003. Available at: http://www.amcp.org/amcp.ark?c= legislative&sc=position&id=1. Accessed October 26, 2006.
18. Community Oncology Alliance. Monitoring patient impact: 2006. Available at: http://communityoncology.org/Default.aspx?tabid=82&ctl=Details&mid= 404&ItemID=737. Accessed October 25, 2006.
19. Reichard J. Payment change is causing shift in where some seniors get pharmaceutical treatment. CQ Healthbeat. Available at: http://www.cmwf.org/ healthpolicyweek/healthpolicyweek_show.htm?doc_id=411569. Accessed November 9, 2006.
20. Robinson JC. Insurers' strategies for managing the use and cost of biopharmaceuticals. Health Aff. 2006;25(5):1205-17.
21. Alder D. Tiers reach new heights under part D. Manag Care. 2006;15(3):63-64.
22. Brixner D. The case against excessive cost-sharing for biologics. Presented at: AMCP Breakfast Symposium: October 2005; Nashville, TN.
23. Gruber J. The role of consumer copayments for health care: lessons from the Rand Health Insurance Experiment and beyond. Available at: http://www.kff.org/insurance/7566.cfm. Accessed November 7, 2006.
24. Goldman DP, Joyce GF, Lawless G, Crown WH, Willey V. Benefit design and specialty drug use. Health Aff. 2006;25(5):1319-31.
25. Mullins, CD, Lavallee, DC, Pradel FG, DeVries AR, Caputo N. Health plans' strategies for managing outpatient specialty pharmaceuticals. Health Aff. 2006;25(5):1332-31.
26. Totten PJ, Goss TF. The impact of payer coverage and reimbursement on off-label use of anticancer therapies. Oncol Issues. January/February 2006. Available at: http://www.accc-cancer.org/ONIS/articles/janfeb06/Totten. pdf. Accessed on October 24, 2006.
27. Monroe CD, Potter L, Millares M, Barreuta A, Wagner R. Kaiser Permanente's evaluation and management of biotech drugs: assessing measuring and affecting use. Health Aff. 2006;25(5):1340-46.
28. Simon F. Market access for biopharmaceuticals: new challenges. Health Aff. 2006;25(5):1363-70.
29. Doan VQ, Chiou CF, Dubois RW. Review of eight pharmacoeconomic studies of the value of biologic DMARDS (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis. J Manag Care Pharm. 2006;12(7):555-69. Available at: http://www.amcp.org/data/jmcp/ subject%20review_555_569.pdf. Accessed November 5, 2006.
30. Health Strategies Group, Inc. MCO Trends in Specialty Pharmacy Management. Lambertville, NJ: HealthStrategies Group; 2004.
31. Watkins JB, Choudhury SR, Wong E, Sullivan SD. Managing biotechnology in a network-model health plan: U.S. private payer perspective. Health Aff. 2006;25(5):1347-52.
32. Anonymous. Applying EBM principles leads to big savings on specialty costs. Spec Pharm News. 2006;(3)8-10.
33. National Institute for Health and Clinical Excellence. Musculoskeletal guidance. Available at: http://www.nice.org.uk/guidance/topic/musculoskeletal/? node=5579&wordid=139. Accessed November 6, 2006.
34. Hagland M. Show me the evidence! Biotechnol Healthc. 2006;3(4):33-38.
35. Medicare Rx Matters. Off-label use of drugs. Available at: http://www.medicarerxmatters.org/People/Professionals/off_label_use.asp. Accessed November 5, 2006.
36. Adams K. The off-label conundrum. Biotechnol Healthc. 2006;3(2):27-34.
37. Herskowitz S. Payers' Dilemma: Looming costs for chronic conditions. Biotechnol Healthc. 2005;2(2):29-34.
38. Academy of Managed Care Pharmacy. The AMCP Format for Formulary Submissions, version 2.1. April 2005. Available at: http://www.fmcpnet.org/ data/resource/Format~Version_2_1~Final_Final.pdf. Accessed November 7, 2006.
39. Marks A. MS Therapy adherence and total health care costs: a specialty pharmacy's role (abstract). Int J MS Care. 2003;5(3):119.
40. Allen JD, Zabriski S, Brown J. Effectiveness of a direct-to-patient specialty pharmacy compliance program (abstract). J Manag Care Pharm. 2005;11(7):602. Available at: http://www.amcp.org/data/jmcp/Abstracts_596_619. pdf. Accessed November 5, 2006.
41. Duong LP, Cantwell AE, Pennybacker BJ, Cocolicchio CJ, Lewis CA. Health outcomes of MS patients managed by a specialty pharmacy (abstract). J Manag Care Pharm. 2005;11(7):610. Available at: http://www.amcp.org/data/jmcp/ Abstracts_596_619.pdf. Accessed November 5, 2006.
42. Berger J et al. Synagis compliance lowers hospitalization rates. Poster presented at: American Academy of Pediatrics Annual Meeting; November 2, 2003; New Orleans, LA.
43. Vogenberg F, Young C, Liebesind D. Biotech injectable drugs: Clinical applications and financial effects. Biotechnol Healthc. 2004;4(4):37-44.